<SEC-DOCUMENT>0001140361-26-016900.txt : 20260427
<SEC-HEADER>0001140361-26-016900.hdr.sgml : 20260427
<ACCEPTANCE-DATETIME>20260427102942
ACCESSION NUMBER:		0001140361-26-016900
CONFORMED SUBMISSION TYPE:	S-8 POS
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20260427
DATE AS OF CHANGE:		20260427
EFFECTIVENESS DATE:		20260427

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMICUS THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001178879
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				200422823
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-8 POS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-257289
		FILM NUMBER:		26897438

	BUSINESS ADDRESS:	
		STREET 1:		47 HULFISH STREET
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08542
		BUSINESS PHONE:		(609) 662-2000

	MAIL ADDRESS:	
		STREET 1:		47 HULFISH STREET
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08542

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMICUS THERAPEUTICS INC
		DATE OF NAME CHANGE:	20020729
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-8 POS
<SEQUENCE>1
<FILENAME>ef20071560_s8pos.htm
<DESCRIPTION>S-8 POS
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div>
      <div style="text-align: center; color: #000000; font-weight: bold;">As filed with the Securities and Exchange Commission on April 27, 2026</div>
      <div>
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      <div style="text-align: right; margin-left: 346.5pt; color: rgb(0, 0, 0); font-weight: bold;">Registration <a name="z_Hlk138974797"></a>No. 333-287807</div>
      <div style="text-align: right; margin-left: 346.3pt; color: rgb(0, 0, 0); font-weight: bold;">Registration No. 333-280055</div>
      <div style="text-align: right; margin-left: 346.3pt; color: rgb(0, 0, 0); font-weight: bold;">Registration No. 333-272621</div>
      <div style="text-align: right; margin-left: 346.3pt; color: rgb(0, 0, 0); font-weight: bold;">Registration No. 333-265531</div>
      <div style="text-align: right; margin-left: 346.3pt; color: rgb(0, 0, 0); font-weight: bold;">Registration No. 333-257289</div>
      <div style="text-align: right; margin-left: 346.3pt; color: rgb(0, 0, 0); font-weight: bold;">Registration No. 333-243779</div>
      <div style="text-align: right; margin-left: 346.3pt; color: rgb(0, 0, 0); font-weight: bold;">Registration No. 333-233153</div>
      <div style="text-align: right; margin-left: 346.3pt; color: rgb(0, 0, 0); font-weight: bold;">Registration No. 333-197202</div>
      <div style="text-align: right; margin-left: 346.3pt; color: rgb(0, 0, 0); font-weight: bold;">Registration No. 333-195194</div>
      <div style="text-align: right; margin-left: 346.3pt; color: rgb(0, 0, 0); font-weight: bold;">Registration No. 333-174900</div>
      <div style="text-align: right; margin-left: 346.3pt; color: rgb(0, 0, 0); font-weight: bold;">Registration No. 333-157219</div>
      <div style="text-align: right; color: #000000; font-weight: bold;">Registration No. 333-145305</div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <div style="text-align: center; color: #000000; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
      <div style="text-align: center; color: #000000; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; color: #000000;"><font style="font-weight: bold;">Washington, D.C. 20549</font>&#160;</div>
      <div>
        <div>
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      </div>
      <div style="text-align: center; color: #000000; font-size: 14pt; font-weight: bold;">POST-EFFECTIVE AMENDMENT NO. 1</div>
      <div style="text-align: center; color: #000000; font-size: 14pt; font-weight: bold;">TO<br>
        FORM S-8&#160;REGISTRATION STATEMENT NO. 333-287807</div>
      <div style="text-align: center; color: #000000; font-size: 14pt; font-weight: bold;">FORM S-8&#160;REGISTRATION STATEMENT NO. 333-280055</div>
      <div style="text-align: center; color: #000000; font-size: 14pt; font-weight: bold;">FORM S-8&#160;REGISTRATION STATEMENT NO. 333-272621</div>
      <div style="text-align: center; color: #000000; font-size: 14pt; font-weight: bold;">FORM S-8&#160;REGISTRATION STATEMENT NO. 333-265531</div>
      <div style="text-align: center; color: #000000; font-size: 14pt; font-weight: bold;">FORM S-8&#160;REGISTRATION STATEMENT NO. 333-257289</div>
      <div style="text-align: center; color: #000000; font-size: 14pt; font-weight: bold;">FORM S-8&#160;REGISTRATION STATEMENT NO. 333-243779</div>
      <div style="text-align: center; color: #000000; font-size: 14pt; font-weight: bold;">FORM S-8&#160;REGISTRATION STATEMENT NO. 333-233153</div>
      <div style="text-align: center; color: #000000; font-size: 14pt; font-weight: bold;">FORM S-8&#160;REGISTRATION STATEMENT NO. 333-197202</div>
      <div style="text-align: center; color: #000000; font-size: 14pt; font-weight: bold;">FORM S-8&#160;REGISTRATION STATEMENT NO. 333-195194</div>
      <div style="text-align: center; color: #000000; font-size: 14pt; font-weight: bold;">FORM S-8&#160;REGISTRATION STATEMENT NO. 333-174900</div>
      <div style="text-align: center; color: #000000; font-size: 14pt; font-weight: bold;">FORM S-8&#160;REGISTRATION STATEMENT NO. 333-157219</div>
      <div style="text-align: center; color: #000000; font-size: 14pt; font-weight: bold;">FORM S-8&#160;REGISTRATION STATEMENT NO. 333-145305</div>
      <div style="text-align: center; color: #000000; font-size: 12pt; font-style: italic; font-weight: bold;">UNDER</div>
      <div style="text-align: center; color: #000000; font-size: 12pt;"><font style="font-weight: bold; font-style: italic;">THE SECURITIES ACT OF 1933</font>&#160;</div>
      <div>
        <div>
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      </div>
      <div style="text-align: center; color: #000000; font-size: 14pt; font-weight: bold;">AMICUS THERAPEUTICS, INC.</div>
      <div style="text-align: center; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">(Exact name of registrant as specified in its charter) </font>&#160;</div>
      <div>
        <div>
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" id="zd51e6f06c9e247a78fc040ede5eabd33" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50.09%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Delaware</div>
            </td>
            <td style="width: 1.82%; vertical-align: bottom;">
              <div>&#160;</div>
            </td>
            <td style="width: 48.1%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;">71-0869350</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50.09%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-size: 8pt; font-weight: bold;">(State or other jurisdiction of</div>
              <div style="text-align: center; color: #000000; font-size: 8pt; font-weight: bold;">incorporation or organization)</div>
            </td>
            <td style="width: 1.82%; vertical-align: bottom;">
              <div style="color: #000000; font-size: 8pt;">&#160;</div>
            </td>
            <td style="width: 48.1%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-size: 8pt; font-weight: bold;">(I.R.S. Employer</div>
              <div style="text-align: center; color: #000000; font-size: 8pt; font-weight: bold;">Identification Number)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50.09%; vertical-align: top;">&#160;</td>
            <td style="width: 1.82%; vertical-align: bottom;">&#160;</td>
            <td style="width: 48.1%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50.09%; vertical-align: top;" rowspan="2">
              <div style="text-align: center; color: #000000; font-weight: bold;">47 Hulfish Street</div>
              <div style="text-align: center; color: #000000; font-weight: bold;">Princeton, New Jersey</div>
            </td>
            <td style="width: 1.82%; vertical-align: bottom;">&#160;</td>
            <td style="width: 48.1%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 1.82%; vertical-align: bottom;">&#160;</td>
            <td style="width: 48.1%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-weight: bold;">08542</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50.09%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-size: 8pt; font-weight: bold;">(Address of Principal Executive Offices)</div>
            </td>
            <td style="width: 1.82%; vertical-align: bottom;">&#160;</td>
            <td style="width: 48.1%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-size: 8pt; font-weight: bold;">(Zip Code)</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">AMICUS THERAPEUTICS, INC. 2002 EQUITY INCENTIVE PLAN, AS AMENDED</div>
      <div style="text-align: center; font-weight: bold;">AMICUS THERAPEUTICS, INC. 2007 EQUITY INCENTIVE PLAN</div>
      <div style="text-align: center; font-weight: bold;">AMICUS THERAPEUTICS, INC. 2007 DIRECTOR OPTION PLAN</div>
      <div style="text-align: center; font-weight: bold;">AMICUS THERAPEUTICS, INC. 2007 EMPLOYEE STOCK PURCHASE PLAN</div>
      <div style="text-align: center; font-weight: bold;">AMENDED AND RESTATED AMICUS THERAPEUTICS, INC. 2007 EQUITY INCENTIVE PLAN</div>
      <div style="text-align: center; font-weight: bold;">AMENDED AND RESTATED AMICUS THERAPEUTICS, INC. 2007 DIRECTOR OPTION PLAN</div>
      <div style="text-align: center; font-weight: bold;">AMICUS THERAPEUTICS, INC. 2023 EMPLOYEE STOCK PURCHASE PLAN</div>
      <div style="text-align: center; font-weight: bold;">AMICUS THERAPEUTICS, INC. 2025 EQUITY INCENTIVE PLAN</div>
      <div style="text-align: center; font-weight: bold;">AMICUS THERAPEUTICS, INC. CASH DEFERRAL PLAN<br>
        AMICUS THERAPEUTICS, INC. RESTRICTED STOCK UNIT DEFERRAL PLAN</div>
      <div><br>
      </div>
      <div style="text-align: center; font-size: 8pt; font-weight: bold;">(Full title of the plans)</div>
      <div><br>
      </div>
      <div style="text-align: center; color: #000000; font-weight: bold;">G. Eric Davis</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">President</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">Amicus Therapeutics, Inc.</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">47 Hulfish Street</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">Princeton, New Jersey 08542</div>
      <div style="text-align: center; color: #000000; font-size: 8pt; font-weight: bold;">(Name and address of agent for service)</div>
      <div><br>
      </div>
      <div style="text-align: center; color: #000000; font-weight: bold;">(609) 662-2000</div>
      <div style="text-align: center; color: #000000; font-size: 8pt; font-weight: bold;">(Telephone Number of Agent for Service)</div>
      <div>
        <div>
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      </div>
      <div style="text-align: center; color: #000000; font-style: italic; font-weight: bold;">Copy to:</div>
      <table cellspacing="0" cellpadding="0" id="z93a9170c1f7a4a3d9439c6726602060b" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 34.05%; vertical-align: middle;">&#160;</td>
            <td style="width: 0.98%; vertical-align: bottom;">&#160;</td>
            <td style="width: 32.04%; vertical-align: middle;">&#160;</td>
            <td style="width: 0.98%; vertical-align: bottom;">&#160;</td>
            <td style="width: 31.94%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 34.05%; vertical-align: top;">&#160;</td>
            <td style="width: 0.98%; vertical-align: bottom;">&#160;</td>
            <td style="width: 32.04%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Jonn R. Beeson</div>
              <div style="text-align: center; color: #000000; font-weight: bold;">Jones Day</div>
              <div style="text-align: center; color: #000000; font-weight: bold;">3161 Michelson Drive, Suite 800</div>
              <div style="text-align: center; color: #000000; font-weight: bold;">Irvine, CA 92612</div>
              <div style="text-align: center; color: #000000; font-weight: bold;">(949) 851-3939</div>
            </td>
            <td style="width: 0.98%; vertical-align: bottom;">&#160;</td>
            <td style="width: 31.94%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div>
        <div>
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      </div>
      <div>Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging
        growth company. See the definitions of <font style="color: #000000;">&#8220;</font>large accelerated filer,<font style="color: #000000;">&#8221;</font>&#160;<font style="color: #000000;">&#8220;</font>accelerated filer,<font style="color: #000000;">&#8221;</font>&#160;<font style="color: #000000;">&#8220;</font>smaller reporting company<font style="color: #000000;">&#8221;</font> and <font style="color: #000000;">&#8220;</font>emerging
        growth company<font style="color: #000000;">&#8221;</font> in Rule 12b-2 of the Exchange Act.</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z229a1285a8de4abf852a2be1c7dcbfca" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 20.67%; vertical-align: bottom;">
              <div>Large accelerated filer</div>
            </td>
            <td style="width: 1.82%; vertical-align: bottom;">
              <div>&#160;</div>
            </td>
            <td style="width: 45.31%; vertical-align: bottom;">
              <div style="color: #000000; font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</div>
            </td>
            <td style="width: 1.82%; vertical-align: bottom;">
              <div>&#160;</div>
            </td>
            <td style="width: 25.44%; vertical-align: bottom;">
              <div>Accelerated filer</div>
            </td>
            <td style="width: 1.82%; vertical-align: bottom;">
              <div>&#160;</div>
            </td>
            <td style="width: 3.13%; vertical-align: bottom;">
              <div style="color: #000000; font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 20.67%; vertical-align: middle;">&#160;</td>
            <td style="width: 47.13%; vertical-align: middle;" colspan="2">&#160;</td>
            <td style="width: 27.25%; vertical-align: middle;" colspan="2">&#160;</td>
            <td style="width: 4.95%; vertical-align: middle;" colspan="2">&#160;</td>
          </tr>
          <tr>
            <td style="width: 20.67%; vertical-align: bottom;">
              <div>Non-accelerated filer</div>
            </td>
            <td style="width: 1.82%; vertical-align: bottom;">
              <div>&#160;</div>
            </td>
            <td style="width: 45.31%; vertical-align: bottom;">
              <div style="color: #000000; font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</div>
            </td>
            <td style="width: 1.82%; vertical-align: bottom;">
              <div>&#160;</div>
            </td>
            <td style="width: 25.44%; vertical-align: bottom;">
              <div>Smaller reporting company</div>
            </td>
            <td style="width: 1.82%; vertical-align: bottom;">
              <div>&#160;</div>
            </td>
            <td style="width: 3.13%; vertical-align: bottom;">
              <div style="color: #000000; font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 20.67%; vertical-align: middle;">&#160;</td>
            <td style="width: 47.13%; vertical-align: middle;" colspan="2">&#160;</td>
            <td style="width: 27.25%; vertical-align: middle;" colspan="2">&#160;</td>
            <td style="width: 4.95%; vertical-align: middle;" colspan="2">&#160;</td>
          </tr>
          <tr>
            <td style="width: 20.67%; vertical-align: bottom;">&#160;</td>
            <td style="width: 1.82%; vertical-align: bottom;">
              <div>&#160;</div>
            </td>
            <td style="width: 45.31%; vertical-align: bottom;">&#160;</td>
            <td style="width: 1.82%; vertical-align: bottom;">
              <div>&#160;</div>
            </td>
            <td style="width: 25.44%; vertical-align: bottom;">
              <div>Emerging growth company</div>
            </td>
            <td style="width: 1.82%; vertical-align: bottom;">
              <div>&#160;</div>
            </td>
            <td style="width: 3.13%; vertical-align: bottom;">
              <div style="color: #000000; font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</div>
            </td>
          </tr>

      </table>
      <div>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
        financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. <font style="font-family: 'Segoe UI Symbol', sans-serif; color: #000000;">&#9744;</font></div>
      <div>
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><font style="font-family: 'Segoe UI Symbol', sans-serif; color: #000000;"> </font></div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">DEREGISTRATION OF SECURITIES</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt;">These Post-Effective Amendments (the &#8220;Post-Effective Amendments&#8221;) relate to the following Registration Statements on Form S-8 (the &#8220;Registration
        Statements&#8221;) filed by Amicus Therapeutics, Inc. (&#8220;Amicus&#8221;) with the Securities and Exchange Commission (the &#8220;SEC&#8221;):</div>
      <div><br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z7ab33397726e4af48f928a9a73f204d6" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 54pt; vertical-align: top; text-align: right;">
                <div style="text-align: left; margin-left: 36pt;">&#8226;</div>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div>Registration Statement No. <font style="color: #000000;">333-287807</font>, filed with the SEC on June 5,
                  2025, relating to the registration of (i) 17,476,463 shares of the common stock of Amicus, par value $0.01 per share (the &#8220;Shares&#8221;), under the Amicus Therapeutics, Inc. 2025 Equity Incentive Plan and (ii) 7,783,410 Shares under the
                  Amended and Restated Amicus Therapeutics, Inc. 2007 Equity Incentive Plan (the &#8220;Amended and Restated 2007 Equity Incentive Plan&#8221;);</div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z84ff457b82824dba9b5b04650aebfa58" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 54pt; vertical-align: top; text-align: right;">
                <div style="text-align: left; margin-left: 36pt;">&#8226;</div>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div>Registration Statement No. <font style="color: #000000;">333-280055</font>, filed with the SEC on June 7,
                  2024, relating to the registration of 7,000,000 Shares under the Amended and Restated 2007 Equity Incentive Plan;</div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z998423267444478aab574631040ab522" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 54pt; vertical-align: top; text-align: right;">
                <div style="text-align: left; margin-left: 36pt;">&#8226;</div>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div>Registration Statement No. <font style="color: #000000;">333-272621</font>, filed with the SEC on June 13,
                  2023, relating to the registration of (i) 2,850,000 Shares for issuance under the Amicus Therapeutics, Inc. 2023 Employee Stock Purchase Plan and (ii) 5,000,000 Shares under the Amended and Restated 2007 Equity Incentive Plan;</div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="ze72960156caf4e96ab7f80fd64cc7573" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 54pt; vertical-align: top; text-align: right;">
                <div style="text-align: left; margin-left: 36pt;">&#8226;</div>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div>Registration Statement No. <font style="color: #000000;">333-265531</font>, filed with the SEC on June 10,
                  2022, relating to the registration of 6,000,000 Shares under the Amended and Restated 2007 Equity Incentive Plan;</div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="zf77c347953054b24b63de3811a3b60e0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 54pt; vertical-align: top; text-align: right;">
                <div style="text-align: left; margin-left: 36pt;">&#8226;</div>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div>Registration Statement No. <font style="color: #000000;">333-257289</font>, filed with the SEC on June 22,
                  2021, relating to the registration of 7,000,000 Shares under the Amended and Restated 2007 Equity Incentive Plan;</div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z97a9d4bac25a4ba0890d5ac1d00c9fa2" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 54pt; vertical-align: top; text-align: right;">
                <div style="text-align: left; margin-left: 36pt;">&#8226;</div>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div>Registration Statement No. <font style="color: #000000;">333-243779</font>, filed with the SEC on August 11,
                  2020, relating to the registration of (i) 9,500,000 Shares under the Amended and Restated 2007 Equity Incentive Plan and (ii) 595,126 Shares under the Amended and Restated Amicus Therapeutics, Inc. 2007 Director Option Plan (the &#8220;Amended
                  and Restated 2007 Director Option Plan&#8221;);</div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="zfb522afb680e40b489a6a7ec4a313e6d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 54pt; vertical-align: top; text-align: right;">
                <div style="text-align: left; margin-left: 36pt;">&#8226;</div>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div>Registration Statement No. <font style="color: #000000;">333-233153</font>, filed with the SEC on August 8,
                  2019, relating to the registration of 12,000,000 Shares under the Amended and Restated 2007 Equity Incentive Plan;</div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z11726fafb18f457d85b7401f8019caa0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 54pt; vertical-align: top; text-align: right;">
                <div style="text-align: left; margin-left: 36pt;">&#8226;</div>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div>Registration Statement No. <font style="color: #000000;">333-197202</font>, filed with the SEC on July 2,
                  2014, relating to the registration of $20,000,000 of deferred compensation obligations under the Amicus Therapeutics, Inc. Cash Deferral Plan;</div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z3b90ea40d8e844acbd170eba936a4262" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 54pt; vertical-align: top; text-align: right;">
                <div style="text-align: left; margin-left: 36pt;">&#8226;</div>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div>Registration Statement No. <font style="color: #000000;">333-195194</font>, filed with the SEC on April 10,
                  2014, relating to the registration of $20,000,000 of deferred compensation obligations under the Amicus Therapeutics, Inc. Restricted Stock Unit Deferral Plan;</div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z525cd156e0594e31bd69bd0ea5f52bf3" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 54pt; vertical-align: top; text-align: right;">
                <div style="text-align: left; margin-left: 36pt;">&#8226;</div>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div>Registration Statement No. <font style="color: #000000;">333-174900</font>, filed with the SEC on June 15,
                  2011, relating to the registration of (i) 7,000,000 Shares under the Amended and Restated 2007 Equity Incentive Plan and (ii) 360,798 Shares under the Amended and Restated 2007 Director Option Plan;</div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z40637822ca14486eabb84e4df4cbd392" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 54pt; vertical-align: top; text-align: right;">
                <div style="text-align: left; margin-left: 36pt;">&#8226;</div>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div>Registration Statement No. <font style="color: #000000;">333-157219</font>, filed with the SEC on February 10,
                  2009, relating to the registration of (i) 2,000,000 Shares under the Amended and Restated 2007 Equity Incentive Plan and (ii) 126,423 Shares under the Amicus Therapeutics, Inc. 2007 Director Option Plan (the &#8220;2007 Director Option Plan&#8221;);
                  and</div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="zbef41cb926784bb9b8eddfbea1794bdd" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 54pt; vertical-align: top; text-align: right;">
                <div style="text-align: left; margin-left: 36pt;">&#8226;</div>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div>Registration Statement No. <font style="color: #000000;">333-145305</font>, filed with the SEC on August 10,
                  2007, relating to (i) the registration of 2,501,307 Shares under the Amicus Therapeutics, Inc. 2002 Equity Incentive Plan, as amended, (ii) 966,667 Shares under the Amicus Therapeutics, Inc. 2007 Equity Incentive Plan, (iii) 200,000
                  Shares under the 2007 Director Option Plan and (iv) 200,000 Shares under the Amicus Therapeutics, Inc. 2007 Employee Stock Purchase Plan.</div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div style="text-indent: 36pt;">On April 27, 2026, Lynx Merger Sub 1, Inc., a Delaware corporation (&#8220;Merger Sub&#8221;) and a wholly owned subsidiary of BioMarin Pharmaceutical Inc., a
        Delaware corporation (&#8220;Parent&#8221;), completed its merger (the &#8220;Merger&#8221;) with and into Amicus pursuant to the terms of the Agreement and Plan of Merger, dated December 19, 2025, by and among Parent, Merger Sub and Amicus.&#160; Amicus was the surviving
        corporation in the Merger and, as a result, is now a wholly owned subsidiary of Parent.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt;">As a result of the Merger, all offerings and sales of securities pursuant to the Registration Statements have been terminated.&#160; In accordance with an
        undertaking made by Amicus in the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities that had been registered for issuance under the Registration Statements that remain unsold at the
        termination of such offerings, Amicus hereby removes from registration all of such securities registered but remaining unsold under the Registration Statements as of the date hereof.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">SIGNATURES</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt;">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the
        requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements described above to be signed on its behalf by the undersigned, thereunto duly authorized, in Princeton, New Jersey, on April 27,
        2026.</div>
      <div><br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" border="0" id="z377ef292762f420ba82bda932530a11b" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

            <tr>
              <td style="width: 55%; vertical-align: top;">&#160;</td>
              <td style="vertical-align: top;" rowspan="1" colspan="2">
                <div>AMICUS THERAPEUTICS, INC.</div>
              </td>
            </tr>
            <tr>
              <td style="width: 55%; vertical-align: top;">&#160;</td>
              <td style="width: 5%; vertical-align: top;">&#160;</td>
              <td style="width: 40%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 55%; vertical-align: top;">&#160;</td>
              <td style="width: 5%; vertical-align: top;">
                <div>By:</div>
              </td>
              <td style="width: 40%; vertical-align: top; border-bottom: 2px solid black;">
                <div>/s/ G. Eric Davis</div>
              </td>
            </tr>
            <tr>
              <td style="width: 55%; vertical-align: top;">&#160;</td>
              <td style="width: 5%; vertical-align: top;">
                <div>Name:</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div>G. Eric Davis</div>
              </td>
            </tr>
            <tr>
              <td style="width: 55%; vertical-align: top;">&#160;</td>
              <td style="width: 5%; vertical-align: top;">
                <div>Title:</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div>President</div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div>No other person is required to sign these Post-Effective Amendments in reliance on Rule 478 of the Securities Act of 1933.</div>
      <div> <br>
      </div>
      <div> <br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
